Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

323.86USD
23 Feb 2018
Change (% chg)

$8.04 (+2.55%)
Prev Close
$315.82
Open
$318.06
Day's High
$323.89
Day's Low
$315.40
Volume
265,685
Avg. Vol
326,313
52-wk High
$543.50
52-wk Low
$313.86

Select another date:

Thu, Feb 8 2018

Regeneron CEO says fears over Eylea 'greatly exaggerated'

Fears of the demise of blockbuster eye drug Eylea were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company's fourth-quarter results.

UPDATE 3-Regeneron CEO says fears over Eylea "greatly exaggerated"

* Shares rise as much as 5 percent (Adds CEO, president comments; updates share price)

BRIEF-Regeneron Reports Q4 Adj. Earnings Per Share $5.23

* REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

Regeneron posts 31 percent drop in quarterly profit

Feb 8 Regeneron Pharmaceuticals Inc's quarterly profit fell about 31 percent on Thursday, due to a charge of $381 million related to changes in U.S. tax laws.

Regeneron forms consortium to accelerate gene sequencing project

Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates.

UPDATE 1-Regeneron forms consortium to accelerate gene sequencing project

Jan 8 Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates.

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS, Jan 8 France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy

* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY

BRIEF-Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi

* REGENERON PHARMACEUTICALS-ON JAN 7,ENTERED LETTER AGREEMENT RELATING TO IMMUNO-ONCOLOGY LICENSE,COLLABORATION AGREEMENT WITH SANOFI BIOTECHNOLOGY SAS​

Select another date: